GLP-1 RAs have not only demonstrated metabolic effects, such as tight glycemic control, but have also recently been recognized for their anti-inflammatory effects by reducing the formation of advanced glycation end products [15]. The anti-inflammatory and weight-reducing properties of GLP-1 RAs might be particularly advantageous for individuals with obesity complicating conditions such as HIV and congestive heart failure, providing a complex approach to reducing their elevated risk of cardiovascular disease [1, 4-8]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.